Literature DB >> 34096830

Analysis of epidemiological serosurvey of hepatitis B virus among people under 29 years of age in Jiangsu Province, China.

Xiang Sun1, Yuanyuan Zhu1, Fenyang Tang1, Xiuying Deng1, Zhiguo Wang1, Yuanbao Liu1.   

Abstract

Background: The purpose of this paper was to analyze the prevalence of hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (anti-HBs), and hepatitis B core anti-body (anti-HBc)in1-29 years old living in the most populous eastern province of China,22 years after introduction of hepatitis B vaccine (HepB) vaccination of infants and provide provincial baseline data for developping a better prevention and control plan for hepatitis B virus (HBV)in Jiangsu Province, China
Methods: The incidence rates of HBV in Jiangsu province from 2004 to 2014 were obtained from the National Notifiable Disease Reporting System (NNDRS). A stratified cluster random sampling method was used to select 3,002 participants aged 1-29 years across 13 HBV monitoring points throughout the province, which had been classified as either urban or rural. HBV serological markers were measured by Abbott microparticle enzyme immunoassay (MEIA) kits (Abbott Laboratories, Chicago, Illinois).
Results: The incidence of hepatitis B decreased by approximately 71.44% in Jiangsu province between 2004 and 2014. Serological assessments showed that the prevalence of the HBsAg, anti-HBc, and anti-HBsin the 1-29 age group were 1.20%, 5.33%,and 66.89%, respectively. There was a significantly lower prevalence of HepB who were vaccinated than in unvaccinated subjects (0.46% vs 14.93%, p < .0001). Among these the ages of 1-29, the coverage rate drops from 97.7% to 56.6% with age,andthe timely rate among people aged 1-14 years was 90.93%.Conclusions: Since the HepB was integrated into the immunization programme in Jiangsu province,the rate of hepatitis B reported and the prevalence of HBsAg decreased significantly, and the coverage of HepB and the vaccination rate within 24 hours after birth have played an important role in reducing HBV infection.

Entities:  

Keywords:  Hepatitis B; immunization; serosurvey

Mesh:

Substances:

Year:  2021        PMID: 34096830      PMCID: PMC8437554          DOI: 10.1080/21645515.2021.1928461

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   4.526


  20 in total

Review 1.  Hepatitis B immunisation for newborn infants of hepatitis B surface antigen-positive mothers.

Authors:  C Lee; Y Gong; J Brok; E H Boxall; C Gluud
Journal:  Cochrane Database Syst Rev       Date:  2006-04-19

2.  The long-term efficacy, 13-23 years, of a plasma-derived hepatitis B vaccine in highly endemic areas in China.

Authors:  Feng Wang; Liping Shen; Fuqiang Cui; Shuang Zhang; Hui Zheng; Yong Zhang; Xiaofeng Liang; Fuzhen Wang; Shengli Bi
Journal:  Vaccine       Date:  2015-04-02       Impact factor: 3.641

3.  Psychometrics of chronic liver disease questionnaire in Chinese chronic hepatitis B patients.

Authors:  Kai-Na Zhou; Min Zhang; Qian Wu; Zhen-Hao Ji; Xiao-Mei Zhang; Gui-Hua Zhuang
Journal:  World J Gastroenterol       Date:  2013-06-14       Impact factor: 5.742

Review 4.  Update on epidemiology of hepatitis B and C in China.

Authors:  Yan Cui; Jidong Jia
Journal:  J Gastroenterol Hepatol       Date:  2013-08       Impact factor: 4.029

5.  Significant reduction in notification and seroprevalence rates of hepatitis B virus infection among the population of Zhejiang Province, China, aged between 1 and 29years from 2006 to 2014.

Authors:  Yang Zhou; Hanqing He; Xuan Deng; Rui Yan; Xuewen Tang; Shuyun Xie; Jun Yao
Journal:  Vaccine       Date:  2017-07-04       Impact factor: 3.641

Review 6.  Strategy vaccination against Hepatitis B in China.

Authors:  Xueyan Liao; Zhenglun Liang
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

7.  Long-term protection at 20-31 years after primary vaccination with plasma-derived hepatitis B vaccine in a Chinese rural community.

Authors:  Jing-Chen Ma; Zhi-Wei Wu; Hai-Song Zhou; Zhao Gao; Zhi-Yong Hao; Fei Jin; Yan-Hong Zhang; Min-Jie Li; Feng Wang; Qi Li; Sheng-Li Bi; Yu-Liang Zhao
Journal:  Hum Vaccin Immunother       Date:  2019-08-29       Impact factor: 3.452

8.  Impact of hepatitis B vaccination in a highly endemic area of south Italy and long-term duration of anti-HBs antibody in two cohorts of vaccinated individuals.

Authors:  Giuliano Da Villa; Luisa Romanò; Alessio Sepe; Raffaele Iorio; Nunzio Paribello; Alessandra Zappa; Alessandro R Zanetti
Journal:  Vaccine       Date:  2007-01-22       Impact factor: 3.641

Review 9.  Epidemiology and Management of Hepatocellular Carcinoma.

Authors:  Laura Kulik; Hashem B El-Serag
Journal:  Gastroenterology       Date:  2018-10-24       Impact factor: 22.682

10.  Long-term effectiveness of plasma-derived hepatitis B vaccine 22-28 years after immunization in a hepatitis B virus endemic rural area: is an adult booster dose needed?

Authors:  H Li; G J Li; Q Y Chen; Z L Fang; X Y Wang; C Tan; Q L Yang; F Z Wang; F Wang; S Zhang; S L Bi; L P Shen
Journal:  Epidemiol Infect       Date:  2017-01-09       Impact factor: 4.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.